IM156 (HL156A; HL271 acetate), a chemical derivative of Metformin , is a potent and orally active AMPK activator that increases AMPK phosphorylation. IM156 attenuates aging-associated cognitive impairment in animal model IM156 is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors
In Vitro
IM156 (0.31-10 μM) phosphorylates AMPKα1 Thr172 in a dose- and time-dependent manner in NIH3T3 mouse fibroblast cells. IM156 does not affect the expression of key factors involved in glucose homeostasis such as glucose-6-phosphatase (G6pase) or phosphoenolpyruvate carboxykinase 1 (Pck1). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: NIH3T3 cells Concentration: 0.31 μM, 0.62 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM Incubation Time: 4 hours Result: Significantly increased the AMPK phosphorylation rate.
In Vivo
IM156 does not affect metabolic regulation assessed by body weight, blood glucose, insulin levels and lipid metabolite content in mice with diet-induced obesity . IM156 (50 mg/kg; for 2 months) does not affect body weight, general locomotion, or anxiety. IM156 significantly attenuates the aging-induced decline in novel object recognition memory and spatial working memory. IM156 significantly increases AMPK activation in the hippocampus of aged mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6J mice (young group/12-16 weeks, old groups/20-22 months)Dosage: 50 mg/kg Administration: Oral administration (drinking water), for 2 months Result: Attenuated age-related cognitive decline.
Form:Solid
IC50& Target:AMPK, OXPHOS
